Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease predominantly affecting upper and lower motor neurons. Here, the authors outline previous and current efforts to characterize ...

Amyotrophic lateral sclerosis, known as ALS, is a neurodegenerative disorder which affects motor neurons. These are the neuronal cells responsible for muscle innervation, whose degenerations leads ...

Amyotrophic lateral sclerosis, or ALS, attacks nerve cells known as motor neurons in the brain and spinal cord, gradually leading to paralysis. The loss of function of an important gene, C9orf72 ...

Amyotrophic lateral sclerosis (ALS) is a rare motor neuron disorder. Currently, there is no cure for ALS and no treatment to stop or keep the disease from worsening over time. ALS mainly involves ...

Intakes of vitamin C and carotenoids and risk of amyotrophic lateral sclerosis: Pooled results from 5 cohort studies. Annals of Neurology, 2012; DOI: 10.1002/ana.23820 ...

Raffaella Uccelli, Alessandra Binazzi, Pierluigi Altavista, Stefano Belli, Pietro Comba, Marina Mastrantonio, Nicola Vanacore, Geographic distribution of amyotrophic lateral sclerosis through motor ...

Diagnosis pathway for patients with amyotrophic lateral sclerosis: retrospective analysis of the US Medicare longitudinal claims database. BMC Neurol. 2013;13 (1):160. doi: 10.1186/1471-2377-13-160.

July 7, 2022 Degradation of motor neurons, conceptual computer illustration. Amyotrophic lateral sclerosis, also referred to as Lou Gehrig's disease is the most common of the motor neuron diseases.

• Key Amyotrophic Lateral Sclerosis Pipeline Therapies: ION363, FB418, SRK-015, RNS60, QRL-201, SAR443820, MN-166, VM202, VRG-50635, Zilucoplan, and others.

Amyotrophic lateral sclerosis (ALS) is a life-threatening neurodegenerative disorder with a two- to three-year median survival after the appearance of symptoms. ALS mainly affects upper and lower ...

Amyotrophic Lateral Sclerosis, ALS, is a horrible disease. Last week in a reversal of a decision the FDA made just a few months ago, their external advisory board approved a “novel” drug for ALS. What ...